Keywords
Last Name
Institution

VINCENT H. TAM

TitleProfessor
InstitutionUniversity of Houston College of Pharmacy
DepartmentClinical Sciences & Administration
AddressTexas Medical Center Campus, Room 515
1441 Moursund
Houston TX 77030
vCardDownload vCard

    Collapse Additional Tools and Researcher Information 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Grossman TH, Anderson MS, Christ D, Gooldy M, Henning LN, Heine HS, Kindt MV, Lin W, Siefkas-Patterson K, Radcliff AK, Tam VH, Sutcliffe JA. The fluorocycline TP-271 is efficacious in models of aerosolized Francisella tularensis SCHU S4 infection in BALB/c mice and cynomolgus macaques. Antimicrob Agents Chemother. 2017 May 30. PMID: 28559261.
      View in: PubMed
    2. Singh KV, Tran TT, Nannini EC, Tam VH, Arias CA, Murray BE. Efficacy of Ceftaroline in a Rat Model of Endocarditis Against Methicillin-Susceptible Staphylococcus aureus Exhibiting the Cefazolin High Inoculum Effect. Antimicrob Agents Chemother. 2017 May 08. PMID: 28483961.
      View in: PubMed
    3. Tängdén T, Ramos Martín V, Felton TW, Nielsen EI, Marchand S, Brüggemann RJ, Bulitta JB, Bassetti M, Theuretzbacher U, Tsuji BT, Wareham DW, Friberg LE, De Waele JJ, Tam VH, Roberts JA. The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections. Intensive Care Med. 2017 Apr 13. PMID: 28409203.
      View in: PubMed
    4. Tran TT, Tam VH, Murray BE, Arias CA, Singh KV. Efficacy of Telavancin Alone and in Combination with Ampicillin in a Rat Model of Enterococcus faecalis Endocarditis. Antimicrob Agents Chemother. 2017 Mar 20. PMID: 28320712.
      View in: PubMed
    5. Zhou J, Ledesma KR, Chang KT, Abodakpi H, Gao S, Tam VH. Pharmacokinetics and pharmacodynamics of minocycline against Acinetobacter baumannii in a neutropenic murine pneumonia model. Antimicrob Agents Chemother. 2017 Mar 06. PMID: 28264853.
      View in: PubMed
    6. Zhou J, Tran BT, Tam VH. The complexity of minocycline serum protein binding. J Antimicrob Chemother. 2017 Feb 25. PMID: 28333250.
      View in: PubMed
    7. Tam VH, Chang KT, Zhou J, Ledesma KR, Phe K, Gao S, Van Bambeke F, Sánchez-Díaz AM, Zamorano L, Oliver A, Cantón R. Determining ?-lactam exposure threshold to suppress resistance development in Gram-negative bacteria. J Antimicrob Chemother. 2017 Jan 31. PMID: 28158470.
      View in: PubMed
    8. Manchandani P, Zhou J, Babic JT, Ledesma KR, Truong LD, Tam VH. The role of renal drug exposure in polymyxin B-induced nephrotoxicity. Antimicrob Agents Chemother. 2017 Jan 17. PMID: 28096166.
      View in: PubMed
    9. Thamlikitkul V, Dubrovskaya Y, Manchandani P, Ngamprasertchai T, Boonyasiri A, Babic JT, Tam VH. Dosing and Pharmacokinetics of Polymyxin B in Patients with Renal Insufficiency. Antimicrob Agents Chemother. 2017 Jan; 61(1). PMID: 27799209.
      View in: PubMed
    10. Manchandani P, Dubrovskaya Y, Gao S, Tam VH. Comparative Pharmacokinetic Profiling of Different Polymyxin B Components. Antimicrob Agents Chemother. 2016 Oct 3. PMID: 27697755.
      View in: PubMed
    11. Phe K, Shields RK, Tverdek FP, Aitken SL, Guervil DJ, Lam WM, Musgrove RJ, Luce AM, Tam VH. Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohort study. J Antimicrob Chemother. 2016 Dec; 71(12):3585-3587. PMID: 27543655.
      View in: PubMed
    12. Trad MA, Zhong LH, Llorin RM, Tan SY, Chan M, Archuleta S, Sulaiman Z, Tam VH, Lye DC, Fisher DA. Ertapenem in outpatient parenteral antimicrobial therapy for complicated urinary tract infections. J Chemother. 2017 Feb; 29(1):25-29. PMID: 27239695.
      View in: PubMed
    13. Cao H, Phe K, Laine GA, Russo HR, Putney KS, Tam VH. An institutional review of antimicrobial stewardship interventions. J Glob Antimicrob Resist. 2016 Sep; 6:75-7. PMID: 27530844.
      View in: PubMed
    14. Manchandani P, Zhou J, Ledesma KR, Truong LD, Chow DS, Eriksen JL, Tam VH. Characterization of Polymyxin B Bio-distribution and Disposition in an Animal Model. Antimicrob Agents Chemother. 2015 Dec 7. PMID: 26643340.
      View in: PubMed
    15. Aitken SL, Zhou J, Ghantoji SS, Kontoyiannis DP, Jones RB, Tam VH, Chemaly RF. Pharmacokinetics and safety of intravesicular cidofovir in allogeneic HSCT recipients. J Antimicrob Chemother. 2016 Mar; 71(3):727-30. PMID: 26612873.
      View in: PubMed
    16. Patel TS, Cottreau JM, Hirsch EB, Tam VH. Impact of hyperglycemia on outcomes of patients with Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis. 2016 Feb; 84(2):155-8. PMID: 26639227.
      View in: PubMed
    17. Zhang D, Wu L, Chow DS, Tam VH, Rios DR. Quantitative determination of dopamine in human plasma by a highly sensitive LC-MS/MS assay: Application in preterm neonates. J Pharm Biomed Anal. 2016 Jan 5; 117:227-31. PMID: 26372947.
      View in: PubMed
    18. Abodakpi H, Gohlke J, Chang KT, Chow DS, Tam VH. Analytical and functional determination of polymyxin B protein binding in serum. Antimicrob Agents Chemother. 2015 Nov; 59(11):7121-3. PMID: 26324262.
      View in: PubMed
    19. Bowers DR, Cao H, Zhou J, Ledesma KR, Sun D, Lomovskaya O, Tam VH. Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii. Antimicrob Agents Chemother. 2015 May; 59(5):2720-5. PMID: 25712362; PMCID: PMC4394818.
    20. Tam VH, Ledesma KR, Bowers DR, Zhou J, Truong LD. Kidney injury associated with telavancin dosing regimen in an animal model. Antimicrob Agents Chemother. 2015 May; 59(5):2930-3. PMID: 25712358; PMCID: PMC4394766.
    21. Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH. Risk factors for nephrotoxicity onset associated with polymyxin B therapy. J Antimicrob Chemother. 2015 Jun; 70(6):1903-7. PMID: 25652747.
      View in: PubMed
    22. Aitken SL, Altshuler J, Guervil DJ, Hirsch EB, Ostrosky-Zeichner LL, Ericsson CD, Tam VH. Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia. Int J Antimicrob Agents. 2015 May; 45(5):541-4. PMID: 25665726.
      View in: PubMed
    23. Phe K, Dao D, Palmer HR, Tam VH. In vitro ceftriaxone susceptibility in methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2015 Feb; 59(2):1370. PMID: 25403674; PMCID: PMC4335838.
    24. Zasowski E, Bland CM, Tam VH, Lodise TP. Identification of optimal renal dosage adjustments for high-dose extended-infusion cefepime dosing regimens in hospitalized patients. J Antimicrob Chemother. 2015 Mar; 70(3):877-81. PMID: 25381169.
      View in: PubMed
    25. Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JD. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis. 2015 Feb; 15(2):225-34. PMID: 25459221.
      View in: PubMed
    26. Abdelraouf K, Tam VH. Reply to "measuring polymyxin uptake by renal tubular cells: is BODIPY-polymyxin B an appropriate probe?". Antimicrob Agents Chemother. 2014 Oct; 58(10):6339. PMID: 25225341; PMCID: PMC4187904.
    27. Bernhardt MB, Moffett BS, Johnson M, Tam VH, Thompson P, Garey KW. Agreement among measurements and estimations of glomerular filtration in children with cancer. Pediatr Blood Cancer. 2015 Jan; 62(1):80-4. PMID: 25263332.
      View in: PubMed
    28. Phe K, Johnson ML, Palmer HR, Tam VH. Validation of a model to predict the risk of nephrotoxicity in patients receiving colistin. Antimicrob Agents Chemother. 2014 Nov; 58(11):6946-8. PMID: 25136012; PMCID: PMC4249357.
    29. Zhang D, Rios DR, Tam VH, Chow DS. Development and validation of a highly sensitive LC-MS/MS assay for the quantification of arginine vasopressin in human plasma and urine: Application in preterm neonates and child. J Pharm Biomed Anal. 2014 Oct; 99:67-73. PMID: 25072843.
      View in: PubMed
    30. Tan MW, Lye DC, Ng TM, Nikolaou M, Tam VH. Mathematical model to quantify the effects of risk factors on carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2014 Sep; 58(9):5239-44. PMID: 24957824; PMCID: PMC4135838.
    31. Zhou J, Sulaiman Z, Llorin RM, Hee KH, Lee LS, Lye DC, Fisher DA, Tam VH. Pharmacokinetics of ertapenem in outpatients with complicated urinary tract infections. J Antimicrob Chemother. 2014 Sep; 69(9):2517-21. PMID: 24797063.
      View in: PubMed
    32. Abdelraouf K, Chang KT, Yin T, Hu M, Tam VH. Uptake of polymyxin B into renal cells. Antimicrob Agents Chemother. 2014 Jul; 58(7):4200-2. PMID: 24733472; PMCID: PMC4068554.
    33. Phe K, Lee Y, McDaneld PM, Prasad N, Yin T, Figueroa DA, Musick WL, Cottreau JM, Hu M, Tam VH. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother. 2014 May; 58(5):2740-6. PMID: 24566187; PMCID: PMC3993221.
    34. Hirsch EB, Chang KT, Zucchi PC, Francoeur DN, Ledesma KR, Tam VH, Lasco TM. An evaluation of multiple phenotypic screening methods for Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae. J Infect Chemother. 2014 Mar; 20(3):224-7. PMID: 24674388.
      View in: PubMed
    35. Ou LC, Faulkner C, Tam V, Leiter JC. Liver function in rats acclimatized to a simulated altitude of 5500 m. High Alt Med Biol. 2013 Dec; 14(4):375-82. PMID: 24377345.
      View in: PubMed
    36. Ng TM, Lye DC, Chan M, Tam VH. Predictive performance of pharmacokinetic models for outpatients receiving vancomycin continuous infusion. Int J Antimicrob Agents. 2014 Feb; 43(2):197-9. PMID: 24359843.
      View in: PubMed
    37. Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JD. Consistent global approach on reporting of colistin doses to promote safe and effective use. Clin Infect Dis. 2014 Jan; 58(1):139-41. PMID: 24107410.
      View in: PubMed
    38. He J, Abdelraouf K, Ledesma KR, Chow DS, Tam VH. Pharmacokinetics and efficacy of liposomal polymyxin B in a murine pneumonia model. Int J Antimicrob Agents. 2013 Dec; 42(6):559-64. PMID: 24016799; PMCID: PMC3849129.
    39. Bowers DR, Tam VH. Pseudomonas aeruginosa treatment and transmission reduction. Expert Rev Anti Infect Ther. 2013 Aug; 11(8):831-7. PMID: 23977938.
      View in: PubMed
    40. He J, Gao S, Hu M, Chow DS, Tam VH. A validated ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of polymyxin B in mouse serum and epithelial lining fluid: application to pharmacokinetic studies. J Antimicrob Chemother. 2013 May; 68(5):1104-10. PMID: 23341128; PMCID: PMC3625435.
    41. Tam VH, Hirsch EB, Lasco TM, Gentry LO, Palmer HR. Correlation of hospital carbapenem consumption and resistance trends in selected gram-negative bacteria. Ann Pharmacother. 2012 Jul-Aug; 46(7-8):1120-2. PMID: 22764323.
      View in: PubMed
    42. Abdelraouf K, Braggs KH, Yin T, Truong LD, Hu M, Tam VH. Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design. Antimicrob Agents Chemother. 2012 Sep; 56(9):4625-9. PMID: 22687519; PMCID: PMC3421883.
    43. Tran TT, Palmer HR, Weston J, Hirsch EB, Shah DN, Cottreau J, Tam VH, Garey KW. Evaluation of a daptomycin dose-optimization protocol. Am J Health Syst Pharm. 2012 Jun 1; 69(11):979-84. PMID: 22610031.
      View in: PubMed
    44. Hirsch EB, Ledesma KR, Chang KT, Schwartz MS, Motyl MR, Tam VH. In vitro activity of MK-7655, a novel ?-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother. 2012 Jul; 56(7):3753-7. PMID: 22526311; PMCID: PMC3393460.
    45. Tiong CT, Chen C, Zhang SJ, Li J, Soshilov A, Denison MS, Lee LS, Tam VH, Wong SP, Xu HE, Yong EL. A novel prenylflavone restricts breast cancer cell growth through AhR-mediated destabilization of ER? protein. Carcinogenesis. 2012 May; 33(5):1089-97. PMID: 22345291; PMCID: PMC3334513.
    46. Bhagunde P, Chang KT, Hirsch EB, Ledesma KR, Nikolaou M, Tam VH. Novel modeling framework to guide design of optimal dosing strategies for ?-lactamase inhibitors. Antimicrob Agents Chemother. 2012 May; 56(5):2237-40. PMID: 22330927; PMCID: PMC3346582.
    47. Guo B, Abdelraouf K, Ledesma KR, Nikolaou M, Tam VH. Predicting bacterial fitness cost associated with drug resistance. J Antimicrob Chemother. 2012 Apr; 67(4):928-32. PMID: 22232512.
      View in: PubMed
    48. Singh R, Swick MC, Ledesma KR, Yang Z, Hu M, Zechiedrich L, Tam VH. Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli. Antimicrob Agents Chemother. 2012 Apr; 56(4):1680-5. PMID: 22232279; PMCID: PMC3318314.
    49. Palmer HR, Weston J, Gentry L, Salazar M, Putney K, Frost C, Tipton JA, Cottreau J, Tam VH, Garey KW. Improving patient care through implementation of an antimicrobial stewardship program. Am J Health Syst Pharm. 2011 Nov 15; 68(22):2170-4. PMID: 22058103.
      View in: PubMed
    50. Hirsch EB, Cottreau JM, Chang KT, Caeiro JP, Johnson ML, Tam VH. A model to predict mortality following Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis. 2012 Jan; 72(1):97-102. PMID: 22056006.
      View in: PubMed
    51. Singh R, Tam VH. Optimizing dosage to prevent emergence of resistance - lessons from in vitro models. Curr Opin Pharmacol. 2011 Oct; 11(5):453-6. PMID: 21868287.
      View in: PubMed
    52. Guo B, Abdelraouf K, Ledesma KR, Chang KT, Nikolaou M, Tam VH. Quantitative impact of neutrophils on bacterial clearance in a murine pneumonia model. Antimicrob Agents Chemother. 2011 Oct; 55(10):4601-5. PMID: 21807974; PMCID: PMC3186951.
    53. Tam VH, Cao H, Ledesma KR, Hu M. In vitro potency of various polymyxin B components. Antimicrob Agents Chemother. 2011 Sep; 55(9):4490-1. PMID: 21709096; PMCID: PMC3165278.
    54. Salvatore CM, Abdelraouf K, Hsing DD, Tam VH. Pharmacokinetics of polymyxin B in an infant with multidrug-resistant Klebsiella pneumoniae bacteremia. Pediatr Infect Dis J. 2011 Jun; 30(6):537-9. PMID: 21164382.
      View in: PubMed
    55. Kwa AL, Falagas ME, Michalopoulos A, Tam VH. Benefits of aerosolized colistin for ventilator-associated pneumonia: absence of proof versus proof of absence? Clin Infect Dis. 2011 May; 52(10):1278-9; author reply 1279-80. PMID: 21507926.
      View in: PubMed
    56. Kwa AL, Abdelraouf K, Low JG, Tam VH. Pharmacokinetics of polymyxin B in a patient with renal insufficiency: a case report. Clin Infect Dis. 2011 May; 52(10):1280-1. PMID: 21507928; PMCID: PMC3115279.
    57. Abdelraouf K, Kabbara S, Ledesma KR, Poole K, Tam VH. Effect of multidrug resistance-conferring mutations on the fitness and virulence of Pseudomonas aeruginosa. J Antimicrob Chemother. 2011 Jun; 66(6):1311-7. PMID: 21415038.
      View in: PubMed
    58. Bhagunde P, Singh R, Ledesma KR, Chang KT, Nikolaou M, Tam VH. Modelling biphasic killing of fluoroquinolones: guiding optimal dosing regimen design. J Antimicrob Chemother. 2011 May; 66(5):1079-86. PMID: 21393141.
      View in: PubMed
    59. Hirsch EB, Chang KT, Lasco TM, Caeiro JP, Tam VH. Emergence of KPC-producing Klebsiella pneumoniae in Texas. Diagn Microbiol Infect Dis. 2011 Feb; 69(2):234-5. PMID: 21251574.
      View in: PubMed
    60. Tam VH, Nikolaou M. A novel approach to pharmacodynamic assessment of antimicrobial agents: new insights to dosing regimen design. PLoS Comput Biol. 2011; 7(1):e1001043. PMID: 21253559; PMCID: PMC3017105.
    61. Garey KW, Jiang ZD, Ghantoji S, Tam VH, Arora V, Dupont HL. A common polymorphism in the interleukin-8 gene promoter is associated with an increased risk for recurrent Clostridium difficile infection. Clin Infect Dis. 2010 Dec 15; 51(12):1406-10. PMID: 21058913.
      View in: PubMed
    62. Bhagunde P, Chang KT, Singh R, Singh V, Garey KW, Nikolaou M, Tam VH. Mathematical modeling to characterize the inoculum effect. Antimicrob Agents Chemother. 2010 Nov; 54(11):4739-43. PMID: 20805390; PMCID: PMC2976129.
    63. Hirsch EB, Tam VH. Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes. Expert Rev Pharmacoecon Outcomes Res. 2010 Aug; 10(4):441-51. PMID: 20715920; PMCID: PMC3071543.
    64. Palmer HR, Cottreau JM, Garey KW, Hirsch EB, Musick WL, Tam VH, Yeh RF. Significant publications on infectious diseases pharmacotherapy in 2009. Am J Health Syst Pharm. 2010 Aug; 67(15):e34-42. PMID: 20651305.
      View in: PubMed
    65. Singh R, Ledesma KR, Chang KT, Tam VH. Impact of recA on levofloxacin exposure-related resistance development. Antimicrob Agents Chemother. 2010 Oct; 54(10):4262-8. PMID: 20660686; PMCID: PMC2944593.
    66. He J, Figueroa DA, Lim TP, Chow DS, Tam VH. Stability of polymyxin B sulfate diluted in 0.9% sodium chloride injection and stored at 4 or 25 degrees C. Am J Health Syst Pharm. 2010 Jul 15; 67(14):1191-4. PMID: 20592326.
      View in: PubMed
    67. Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother. 2010 Jun; 65(6):1119-25. PMID: 20378670.
      View in: PubMed
    68. Yuan Z, Ledesma KR, Singh R, Hou J, Prince RA, Tam VH. Quantitative assessment of combination antimicrobial therapy against multidrug-resistant bacteria in a murine pneumonia model. J Infect Dis. 2010 Mar 15; 201(6):889-97. PMID: 20156065.
      View in: PubMed
    69. Tam VH, Chang KT, Abdelraouf K, Brioso CG, Ameka M, McCaskey LA, Weston JS, Caeiro JP, Garey KW. Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010 Mar; 54(3):1160-4. PMID: 20086165; PMCID: PMC2826008.
    70. Hsu LY, Tan TY, Tam VH, Kwa A, Fisher DA, Koh TH. Surveillance and correlation of antibiotic prescription and resistance of Gram-negative bacteria in Singaporean hospitals. Antimicrob Agents Chemother. 2010 Mar; 54(3):1173-8. PMID: 20065055; PMCID: PMC2826017.
    71. He J, Ledesma KR, Lam WY, Figueroa DA, Lim TP, Chow DS, Tam VH. Variability of polymyxin B major components in commercial formulations. Int J Antimicrob Agents. 2010 Mar; 35(3):308-10. PMID: 20045285.
      View in: PubMed
    72. Xu H, Kulkarni KH, Singh R, Yang Z, Wang SW, Tam VH, Hu M. Disposition of naringenin via glucuronidation pathway is affected by compensating efflux transporters of hydrophilic glucuronides. Mol Pharm. 2009 Nov-Dec; 6(6):1703-15. PMID: 19736994; PMCID: PMC2941777.
    73. Kuper KM, Hirsch EB, Tam VH. Significant publications on infectious diseases pharmacotherapy in 2008. Am J Health Syst Pharm. 2009 Oct 1; 66(19):1726-34. PMID: 19767379.
      View in: PubMed
    74. Ingram PR, Lye DC, Fisher DA, Goh WP, Tam VH. Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy. Int J Antimicrob Agents. 2009 Dec; 34(6):570-4. PMID: 19744837.
      View in: PubMed
    75. Tam VH, Ledesma KR, Schilling AN, Lim TP, Yuan Z, Ghose R, Lewis RE. In vivo dynamics of carbapenem-resistant Pseudomonas aeruginosa selection after suboptimal dosing. Diagn Microbiol Infect Dis. 2009 Aug; 64(4):427-33. PMID: 19631096.
      View in: PubMed
    76. Singh R, Ledesma KR, Chang KT, Hou JG, Prince RA, Tam VH. Pharmacodynamics of moxifloxacin against a high inoculum of Escherichia coli in an in vitro infection model. J Antimicrob Chemother. 2009 Sep; 64(3):556-62. PMID: 19589810.
      View in: PubMed
    77. Tam VH, Ledesma KR, Chang KT, Wang TY, Quinn JP. Killing of Escherichia coli by beta-lactams at different inocula. Diagn Microbiol Infect Dis. 2009 Jun; 64(2):166-71. PMID: 19304437.
      View in: PubMed
    78. Garey KW, Vo QP, Larocco MT, Gentry LO, Tam VH. Prevalence of type III secretion protein exoenzymes and antimicrobial susceptibility patterns from bloodstream isolates of patients with Pseudomonas aeruginosa bacteremia. J Chemother. 2008 Dec; 20(6):714-20. PMID: 19129069.
      View in: PubMed
    79. Tam VH, Hou J, Kwa AL, Prince RA. Comment on: Development and validation of a reversed-phase high-performance liquid chromatography assay for polymyxin B in human plasma. J Antimicrob Chemother. 2009 Mar; 63(3):627-8; author reply 628-9. PMID: 19022780.
      View in: PubMed
    80. Yeh RF, Kuper KM, Coyle EA, Garey KW, Ikwuagwu JO, Maclayton DO, Mohr JF, Musick WL, Pass SE, Rios E, Tam VH. Significant publications on infectious diseases pharmacotherapy in 2007. Am J Health Syst Pharm. 2008 Nov 15; 65(22):e72-9. PMID: 18997127.
      View in: PubMed
    81. Garey KW, Vo QP, Lewis RE, Saengcharoen W, LaRocco MT, Tam VH. Increased bacterial adherence and biomass in Pseudomonas aeruginosa bacteria exposed to clarithromycin. Diagn Microbiol Infect Dis. 2009 Jan; 63(1):81-6. PMID: 18990530.
      View in: PubMed
    82. Kwa AL, Low JG, Lim TP, Leow PC, Kurup A, Tam VH. Independent predictors for mortality in patients with positive Stenotrophomonas maltophilia cultures. Ann Acad Med Singapore. 2008 Oct; 37(10):826-30. PMID: 19037515.
      View in: PubMed
    83. Garey KW, Martorell MV, Vo QP, Tam VH. Killing activity of rifampin with piperacillin therapy against adherent cells of Pseumodomas aeruginosa. J Chemother. 2008 Oct; 20(5):652-4. PMID: 19028631.
      View in: PubMed
    84. Kwa AL, Tam VH, Falagas ME. Polymyxins: a review of the current status including recent developments. Ann Acad Med Singapore. 2008 Oct; 37(10):870-83. PMID: 19037522.
      View in: PubMed
    85. Tam VH, Ledesma KR, Vo G, Kabbara S, Lim TP, Nikolaou M. Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development. Antimicrob Agents Chemother. 2008 Nov; 52(11):3987-93. PMID: 18725438; PMCID: PMC2573104.
    86. Lim TP, Ledesma KR, Chang KT, Hou JG, Kwa AL, Nikolaou M, Quinn JP, Prince RA, Tam VH. Quantitative assessment of combination antimicrobial therapy against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2008 Aug; 52(8):2898-904. PMID: 18505848; PMCID: PMC2493134.
    87. Yuan Z, Tam VH. Polymyxin B: a new strategy for multidrug-resistant Gram-negative organisms. Expert Opin Investig Drugs. 2008 May; 17(5):661-8. PMID: 18447592.
      View in: PubMed
    88. Tam VH, Gamez EA, Weston JS, Gerard LN, Larocco MT, Caeiro JP, Gentry LO, Garey KW. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis. 2008 Mar 15; 46(6):862-7. PMID: 18279040.
      View in: PubMed
    89. Ingram PR, Lye DC, Tambyah PA, Goh WP, Tam VH, Fisher DA. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J Antimicrob Chemother. 2008 Jul; 62(1):168-71. PMID: 18334494.
      View in: PubMed
    90. Lim TP, Garey KW, Tam VH. Pharmacokinetic/Pharmacodynamic antimicrobial individualization and optimization strategies. Curr Infect Dis Rep. 2008 Mar; 10(1):9-13. PMID: 18377809.
      View in: PubMed
    91. Liu X, Tam VH, Hu M. Disposition of flavonoids via enteric recycling: determination of the UDP-glucuronosyltransferase isoforms responsible for the metabolism of flavonoids in intact Caco-2 TC7 cells using siRNA. Mol Pharm. 2007 Nov-Dec; 4(6):873-82. PMID: 17927138; PMCID: PMC2597501.
    92. Kwa AL, Lim TP, Low JG, Hou J, Kurup A, Prince RA, Tam VH. Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. Diagn Microbiol Infect Dis. 2008 Feb; 60(2):163-7. PMID: 17916420.
      View in: PubMed
    93. Tam VH, Schilling AN, Poole K, Nikolaou M. Mathematical modelling response of Pseudomonas aeruginosa to meropenem. J Antimicrob Chemother. 2007 Dec; 60(6):1302-9. PMID: 17913722.
      View in: PubMed
    94. Kwa A, Kasiakou SK, Tam VH, Falagas ME. Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev Anti Infect Ther. 2007 Oct; 5(5):811-21. PMID: 17914915.
      View in: PubMed
    95. Tam VH, Chang KT, LaRocco MT, Schilling AN, McCauley SK, Poole K, Garey KW. Prevalence, mechanisms, and risk factors of carbapenem resistance in bloodstream isolates of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 2007 Jul; 58(3):309-14. PMID: 17617302.
      View in: PubMed
    96. Tam VH, Louie A, Fritsche TR, Deziel M, Liu W, Brown DL, Deshpande L, Leary R, Jones RN, Drusano GL. Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial. J Infect Dis. 2007 Jun 15; 195(12):1818-27. PMID: 17492598.
      View in: PubMed
    97. Nikolaou M, Schilling AN, Vo G, Chang KT, Tam VH. Modeling of microbial population responses to time-periodic concentrations of antimicrobial agents. Ann Biomed Eng. 2007 Aug; 35(8):1458-70. PMID: 17431788.
      View in: PubMed
    98. Tam VH, Schilling AN, LaRocco MT, Gentry LO, Lolans K, Quinn JP, Garey KW. Prevalence of AmpC over-expression in bloodstream isolates of Pseudomonas aeruginosa. Clin Microbiol Infect. 2007 Apr; 13(4):413-8. PMID: 17359326.
      View in: PubMed
    99. Kwa AL, Low JG, Lee E, Kurup A, Chee HL, Tam VH. The impact of multidrug resistance on the outcomes of critically ill patients with Gram-negative bacterial pneumonia. Diagn Microbiol Infect Dis. 2007 May; 58(1):99-104. PMID: 17300905.
      View in: PubMed
    100. Falagas ME, Bliziotis IA, Tam VH. Intraventricular or intrathecal use of polymyxins in patients with Gram-negative meningitis: a systematic review of the available evidence. Int J Antimicrob Agents. 2007 Jan; 29(1):9-25. PMID: 17126534.
      View in: PubMed
    101. Tam VH, Louie A, Deziel MR, Liu W, Drusano GL. The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance. Antimicrob Agents Chemother. 2007 Feb; 51(2):744-7. PMID: 17116679; PMCID: PMC1797751.
    102. Tam VH, Kabbara S, Yeh RF, Leary RH. Impact of sample size on the performance of multiple-model pharmacokinetic simulations. Antimicrob Agents Chemother. 2006 Nov; 50(11):3950-2. PMID: 16954312; PMCID: PMC1635223.
    103. Tam VH, Kabbara S. Comparative performance of different stochastic methods to simulate drug exposure and variability in a population. Diagn Microbiol Infect Dis. 2006 Oct; 56(2):185-8. PMID: 16930922.
      View in: PubMed
    104. Tam VH, Kabbara S, Vo G, Schilling AN, Coyle EA. Comparative pharmacodynamics of gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2006 Aug; 50(8):2626-31. PMID: 16870751; PMCID: PMC1538660.
    105. Garey KW, Kumar N, Dao T, Tam VH, Gentry LO. Risk factors for postoperative chest wound infections due to gram-negative bacteria in cardiac surgery patients. J Chemother. 2006 Aug; 18(4):402-8. PMID: 17024796.
      View in: PubMed
    106. Wang SW, Chen J, Jia X, Tam VH, Hu M. Disposition of flavonoids via enteric recycling: structural effects and lack of correlations between in vitro and in situ metabolic properties. Drug Metab Dispos. 2006 Nov; 34(11):1837-48. PMID: 16882763.
      View in: PubMed
    107. Boucher AN, Tam VH. Mathematical formulation of additivity for antimicrobial agents. Diagn Microbiol Infect Dis. 2006 Aug; 55(4):319-25. PMID: 16626903.
      View in: PubMed
    108. Tam VH, Adams S, LaRocco MT, Gerard LN, Gentry LO, Garey KW. An integrated pharmacoeconomic approach to antimicrobial formulary decision-making. Am J Health Syst Pharm. 2006 Apr 15; 63(8):735-9. PMID: 16595813.
      View in: PubMed
    109. Wiederhold NP, Tam VH, Chi J, Prince RA, Kontoyiannis DP, Lewis RE. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2006 Feb; 50(2):469-73. PMID: 16436698; PMCID: PMC1366892.
    110. Lodise TP, Rhoney DH, Tam VH, McKinnon PS, Drusano GL. Pharmacodynamic profiling of cefepime in plasma and cerebrospinal fluid of hospitalized patients with external ventriculostomies. Diagn Microbiol Infect Dis. 2006 Mar; 54(3):223-30. PMID: 16423490.
      View in: PubMed
    111. Jumbe NL, Louie A, Miller MH, Liu W, Deziel MR, Tam VH, Bachhawat R, Drusano GL. Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother. 2006 Jan; 50(1):310-7. PMID: 16377702; PMCID: PMC1346791.
    112. Tam VH, Schilling AN, Neshat S, Poole K, Melnick DA, Coyle EA. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005 Dec; 49(12):4920-7. PMID: 16304153; PMCID: PMC1315965.
    113. Nikolaou M, Tam VH. A new modeling approach to the effect of antimicrobial agents on heterogeneous microbial populations. J Math Biol. 2006 Feb; 52(2):154-82. PMID: 16195922.
      View in: PubMed
    114. Tam VH, Nikolaou M. Mathematical modelling of resistance emergence. J Antimicrob Chemother. 2005 Nov; 56(5):983; author reply 983-4. PMID: 16172104.
      View in: PubMed
    115. Tam VH, Schilling AN, Vo G, Kabbara S, Kwa AL, Wiederhold NP, Lewis RE. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005 Sep; 49(9):3624-30. PMID: 16127031; PMCID: PMC1195418.
    116. Chen J, Wang S, Jia X, Bajimaya S, Lin H, Tam VH, Hu M. Disposition of flavonoids via recycling: comparison of intestinal versus hepatic disposition. Drug Metab Dispos. 2005 Dec; 33(12):1777-84. PMID: 16120792.
      View in: PubMed
    117. Walker P, Neuhauser MN, Tam VH, Willey JS, Palmer JL, Bruera E, Prince RA. Subcutaneous administration of cefepime. J Pain Symptom Manage. 2005 Aug; 30(2):170-4. PMID: 16125032.
      View in: PubMed
    118. Kwa AL, Loh C, Low JG, Kurup A, Tam VH. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis. 2005 Sep 1; 41(5):754-7. PMID: 16080101.
      View in: PubMed
    119. Tam VH, Louie A, Deziel MR, Liu W, Leary R, Drusano GL. Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa. J Infect Dis. 2005 Aug 1; 192(3):420-8. PMID: 15995955.
      View in: PubMed
    120. Tam VH, Schilling AN, Melnick DA, Coyle EA. Comparison of beta-lactams in counter-selecting resistance of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 2005 Jun; 52(2):145-51. PMID: 15964503.
      View in: PubMed
    121. Tam VH, Schilling AN, Nikolaou M. Modelling time-kill studies to discern the pharmacodynamics of meropenem. J Antimicrob Chemother. 2005 May; 55(5):699-706. PMID: 15772138.
      View in: PubMed
    122. Tam VH, Schilling AN, Lewis RE, Melnick DA, Boucher AN. Novel approach to characterization of combined pharmacodynamic effects of antimicrobial agents. Antimicrob Agents Chemother. 2004 Nov; 48(11):4315-21. PMID: 15504858; PMCID: PMC525451.
    123. Wiederhold NP, Kontoyiannis DP, Chi J, Prince RA, Tam VH, Lewis RE. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis. 2004 Oct 15; 190(8):1464-71. PMID: 15378439.
      View in: PubMed
    124. Tam VH, Preston SL, Drusano GL. Comparative pharmacokinetic analysis by standard two-stage method versus nonparametric population modeling. Pharmacotherapy. 2003 Dec; 23(12):1545-9. PMID: 14695034.
      View in: PubMed
    125. Tam VH, Preston SL, Drusano GL. Optimal sampling schedule design for populations of patients. Antimicrob Agents Chemother. 2003 Sep; 47(9):2888-91. PMID: 12936990; PMCID: PMC182630.
    126. Jumbe N, Louie A, Leary R, Liu W, Deziel MR, Tam VH, Bachhawat R, Freeman C, Kahn JB, Bush K, Dudley MN, Miller MH, Drusano GL. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest. 2003 Jul; 112(2):275-85. PMID: 12865415; PMCID: PMC164285.
    127. Tam VH, McKinnon PS, Akins RL, Drusano GL, Rybak MJ. Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function. Antimicrob Agents Chemother. 2003 Jun; 47(6):1853-61. PMID: 12760858; PMCID: PMC155813.
    128. Rhoney DH, Tam VH, Parker D, McKinnon PS, Coplin WM. Disposition of cefepime in the central nervous system of patients with external ventricular drains. Pharmacotherapy. 2003 Mar; 23(3):310-4. PMID: 12627928.
      View in: PubMed
    129. Tam VH, Louie A, Lomaestro BM, Drusano GL. Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa. Pharmacotherapy. 2003 Mar; 23(3):291-5. PMID: 12627925.
      View in: PubMed
    130. Tam VH, McKinnon PS, Akins RL, Rybak MJ, Drusano GL. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother. 2002 Sep; 50(3):425-8. PMID: 12205070.
      View in: PubMed
    131. Lodise TP, McKinnon PS, Tam VH, Rybak MJ. Clinical outcomes for patients with bacteremia caused by vancomycin-resistant enterococcus in a level 1 trauma center. Clin Infect Dis. 2002 Apr 1; 34(7):922-9. PMID: 11880957.
      View in: PubMed
    132. Kwa AL, Tam VH, Rybak MJ. Rhodococcus equi pneumonia in a patient with human immunodeficiency virus: case report and review. Pharmacotherapy. 2001 Aug; 21(8):998-1002. PMID: 11718503.
      View in: PubMed
    133. McKinnon PS, Tam VH. New antibiotics for infections caused by resistant organisms. Support Care Cancer. 2001 Jan; 9(1):8-10. PMID: 11147147.
      View in: PubMed
    134. Tam VH, Mckinnon PS, Levine DP, Brandel SM, Rybak MJ. Once-daily aminoglycoside in the treatment of Enterococcus faecalis endocarditis: case report and review. Pharmacotherapy. 2000 Sep; 20(9):1116-9. PMID: 10999505.
      View in: PubMed
    135. Tam VH, Moore GE, Triller DM, Briceland LL. Vancomycin peak serum concentration monitoring. J Intraven Nurs. 1999 Nov-Dec; 22(6):336-42. PMID: 10865602.
      View in: PubMed
    136. Tam VH, Preston SL, Briceland LL. Once-daily aminoglycosides in the treatment of gram-positive endocarditis. Ann Pharmacother. 1999 May; 33(5):600-6. PMID: 10369625.
      View in: PubMed
    137. Wolfaardt JF, Tam V, Faulkner MG, Prasad N. Mechanical behavior of three maxillofacial prosthetic adhesive systems: a pilot project. J Prosthet Dent. 1992 Dec; 68(6):943-9. PMID: 1494125.
      View in: PubMed
    TAM's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _